Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Vertex Pharmaceuticals
  6. Summary
    VRTX   US92532F1003

VERTEX PHARMACEUTICALS

(VRTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/28/2021 07/29/2021 07/30/2021 08/02/2021 08/03/2021 Date
202.24(c) 200.38(c) 201.58(c) 198.32(c) 199.68 Last
1 258 749 1 396 984 2 132 974 2 809 562 1 181 183 Volume
-0.30% -0.92% +0.60% -1.62% +0.69% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 7 258 M - -
Net income 2021 2 082 M - -
Net cash position 2021 8 095 M - -
P/E ratio 2021 24,7x
Yield 2021 -
Sales 2022 8 020 M - -
Net income 2022 2 893 M - -
Net cash position 2022 11 615 M - -
P/E ratio 2022 18,0x
Yield 2022 -
Capitalization 51 450 M 51 450 M -
EV / Sales 2021 5,97x
EV / Sales 2022 4,97x
Nbr of Employees 3 400
Free-Float 99,6%
More Financials
Company
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination... 
Read more
More about the company
Ratings of Vertex Pharmaceuticals
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about VERTEX PHARMACEUTICALS
08/02VERTEX PHARMACEUTICALS : UBS Adjusts Vertex Pharmaceuticals' Price Target to $25..
MT
07/30VERTEX PHARMACEUTICALS : MA Management's Discussion and Analysis of Financial Co..
AQ
07/30VERTEX PHARMACEUTICALS : Morgan Stanley Adjusts Vertex Pharmaceuticals' Price Ta..
MT
07/30VERTEX PHARMACEUTICALS : SVB Leerink Adjusts Vertex Pharmaceuticals' Price Targe..
MT
07/30VERTEX PHARMACEUTICALS : Goldman Sachs Adjusts Price Target on Vertex Pharmaceut..
MT
07/30VERTEX PHARMACEUTICALS : JPMorgan Adjusts Price Target on Vertex Pharmaceuticals..
MT
07/30VERTEX PHARMACEUTICALS : Piper Sandler Adjusts Price Target on Vertex Pharmaceut..
MT
07/30VERTEX PHARMACEUTICALS : RBC Lifts Price Target on Vertex Pharmaceuticals to $24..
MT
07/29VERTEX PHARMACEUTICALS : Phase 3 study of next-in-class triple combination for C..
PU
07/29VERTEX PHARMACEUTICALS : Q2 Adjusted EPS, Revenue Increase YOY; Raises 2021 Guid..
MT
07/29VERTEX : Q2 Earnings Snapshot
AQ
07/29VERTEX PHARMACEUTICALS INC / MA : Results of Operations and Financial Condition,..
AQ
07/29VERTEX PHARMACEUTICALS : Earnings Flash (VRTX) VERTEX PHARMACEUTICALS INCORPORAT..
MT
07/29VERTEX PHARMACEUTICALS : Earnings Flash (VRTX) VERTEX PHARMACEUTICALS INCORPORAT..
MT
07/29VERTEX PHARMACEUTICALS : Reports Second-Quarter 2021 Financial Results
BU
More news
News in other languages on VERTEX PHARMACEUTICALS
07/23DGAP-NEWS : Biotechbranche mit solidem 2. Quartal -2-
06/18PUMP / DUMP #16  : Les Tops & Flops de la semaine
06/11BOLSA : Madrid cierra al alza al descontarse que aceleración inflación será temp..
04/26VERTEX : NaV1.8-Inhibitor erreicht Phase 2 der klinischen Entwicklung
04/26VERTEX PHARMACEUTICALS : annonce que l'inhibiteur NaV1.8 a progressé vers un dév..
More news
Analyst Recommendations on VERTEX PHARMACEUTICALS
More recommendations
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | VRTX | US92532F1003 | MarketScreener
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Last Close Price 198,32 $
Average target price 263,30 $
Spread / Average Target 32,8%
EPS Revisions
Managers and Directors
Reshma Kewalramani President, Chief Executive Officer & Director
Charles F. Wagner Chief Financial Officer & Executive Vice President
Jeffrey M. Leiden Executive Chairman
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Carmen Bozic Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
VERTEX PHARMACEUTICALS-16.09%51 450
GILEAD SCIENCES, INC.17.22%85 723
BIONTECH SE317.33%82 168
WUXI APPTEC CO., LTD.41.52%69 241
REGENERON PHARMACEUTICALS18.94%59 765
BEIGENE, LTD.26.72%30 464